297 related articles for article (PubMed ID: 19527113)
1. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
2. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
Lu W; Wan J; She Z; Jiang X
J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
[TBL] [Abstract][Full Text] [Related]
3. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier.
Lu W; Tan YZ; Hu KL; Jiang XG
Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009
[TBL] [Abstract][Full Text] [Related]
4. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery.
Lu W; Zhang Y; Tan YZ; Hu KL; Jiang XG; Fu SK
J Control Release; 2005 Oct; 107(3):428-48. PubMed ID: 16176844
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain.
Parikh T; Bommana MM; Squillante E
Eur J Pharm Biopharm; 2010 Mar; 74(3):442-50. PubMed ID: 19941957
[TBL] [Abstract][Full Text] [Related]
6. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice.
Xie YL; Lu W; Jiang XG
Behav Brain Res; 2006 Oct; 173(1):76-84. PubMed ID: 16828890
[TBL] [Abstract][Full Text] [Related]
7. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia.
Liu X; An C; Jin P; Liu X; Wang L
Biomaterials; 2013 Jan; 34(3):817-30. PubMed ID: 23111336
[TBL] [Abstract][Full Text] [Related]
9. The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia.
Liu X; Ye M; An C; Pan L; Ji L
Biomaterials; 2013 Sep; 34(28):6893-905. PubMed ID: 23768781
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
11. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting.
Agarwal A; Agrawal H; Tiwari S; Jain S; Agrawal GP
Int J Pharm; 2011 Dec; 421(1):189-201. PubMed ID: 21986113
[TBL] [Abstract][Full Text] [Related]
12. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
13. In vivo validation of biological responses of bFGF released from microspheres formulated by blending poly-lactide-co-glycolide and poly(ethylene glycol)-grafted-chitosan in hamster cheek pouch microcirculatory models.
Falabella CA; Jiang H; Frame MD; Chen W
J Biomater Sci Polym Ed; 2009; 20(7-8):903-22. PubMed ID: 19454159
[TBL] [Abstract][Full Text] [Related]
14. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
Sant S; Poulin S; Hildgen P
J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
[TBL] [Abstract][Full Text] [Related]
15. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration.
Lu W; Sun Q; Wan J; She Z; Jiang XG
Cancer Res; 2006 Dec; 66(24):11878-87. PubMed ID: 17178885
[TBL] [Abstract][Full Text] [Related]
16. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration.
Wang G; Kucharski C; Lin X; Uludağ H
J Drug Target; 2010 Sep; 18(8):611-26. PubMed ID: 20158316
[TBL] [Abstract][Full Text] [Related]
18. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
[TBL] [Abstract][Full Text] [Related]
20. Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes.
Pang Z; Gao H; Chen J; Shen S; Zhang B; Ren J; Guo L; Qian Y; Jiang X; Mei H
Int J Nanomedicine; 2012; 7():3421-32. PubMed ID: 22848168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
